Fluvoxamine for psychosis in Alzheimer's disease.
Levkovitz
Y
Y
Shalvata Mental Health Center, Israel, Department of Psychiatry, Sackler School of Medicine, Tel Aviv University.
Bloch
Y
Y
Kaplan
D
D
Diskin
A
A
Abramovitchi
I
I
D000208:Acute Disease; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010054:Brief Psychiatric Rating Scale / Q000706:statistics & numerical data; D018592:Cross-Over Studies; D004359:Drug Therapy, Combination; D005260:Female; D016666:Fluvoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010546:Perphenazine / Q000008:administration & dosage / Q000627:therapeutic use*; D010865:Pilot Projects; D010919:Placebos; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D016666:Fluvoxamine; D010546:Perphenazine; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors